Notify me when Blue Water Life Science Advisors, LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | 7 | $109,602,298 | +$5,844,373 | -$28,076,305 | -$22,231,932 | ADPT, GH, NTRA, PSNL, CDNA | 13F-HR | 14 Nov 2025, 10:19 |
| Q2 2025 | 8 | $126,332,680 | +$19,926,296 | -$20,365,680 | -$439,384 | NTRA, ADPT, GH, CDNA, TXG | 13F-HR | 14 Aug 2025, 09:53 |
| Q1 2025 | 7 | $100,917,649 | +$4,191,945 | -$14,015,871 | -$9,823,926 | GH, NTRA, ADPT, CDNA, AKYA | 13F-HR | 15 May 2025, 10:01 |
| Q4 2024 | 9 | $112,936,806 | +$11,230,212 | -$15,658,206 | -$4,427,994 | NTRA, GH, CDNA, ADPT, AKYA | 13F-HR | 13 Feb 2025, 15:38 |
| Q3 2024 | 8 | $113,705,544 | +$32,779,240 | -$39,099,133 | -$6,319,893 | NTRA, CDNA, EXAS, AKYA, ADPT | 13F-HR | 14 Nov 2024, 15:16 |
| Q2 2024 | 8 | $102,826,250 | +$8,610,775 | -$5,822,952 | +$2,787,823 | NTRA, GH, AKYA, CDNA, TXG | 13F-HR | 09 Aug 2024, 12:57 |
| Q1 2024 | 8 | $106,316,114 | +$14,115,922 | -$20,373,151 | -$6,257,229 | NTRA, AKYA, GH, TXG, QTRX | 13F-HR | 15 May 2024, 16:37 |
| Q4 2023 | 9 | $114,165,458 | +$32,457,881 | -$32,774,050 | -$316,169 | NTRA, AKYA, GH, TMO, TXG | 13F-HR | 14 Feb 2024, 16:24 |
| Q3 2023 | 6 | $102,462,003 | +$1,763,000 | -$7,274,591 | -$5,511,591 | NTRA, AKYA, GH, ADPT, NSTG | 13F-HR | 14 Nov 2023, 16:34 |
| Q2 2023 | 9 | $148,155,168 | +$36,902,460 | -$27,781,994 | +$9,120,466 | NTRA, AKYA, GH, ADPT, NSTG | 13F-HR | 14 Aug 2023, 17:34 |
| Q1 2023 | 8 | $151,234,037 | +$13,484,684 | -$10,615,610 | +$2,869,074 | NTRA, ADPT, AKYA, MXCT, GH | 13F-HR | 15 May 2023, 16:20 |
| Q4 2022 | 8 | $148,863,925 | +$18,117,620 | -$26,938,025 | -$8,820,405 | NTRA, GH, ADPT, AKYA, MXCT | 13F-HR | 14 Feb 2023, 08:14 |
| Q3 2022 | 9 | $219,425,368 | +$39,845,328 | +$39,845,328 | GH, NTRA, CTKB, ADPT, AKYA | 13F-HR | 14 Nov 2022, 14:45 | |
| Q2 2022 | 9 | $184,130,000 | +$87,261,735 | -$23,119,413 | +$64,142,322 | GH, NTRA, AKYA, ADPT, CTKB | 13F-HR | 15 Aug 2022, 12:36 |
| Q1 2022 | 10 | $210,714,000 | +$94,212,764 | +$94,212,764 | NTRA, GH, CDNA, PACB, AKYA | 13F-HR | 18 May 2022, 15:22 | |
| Q4 2021 | 13 | $326,892,000 | +$97,663,220 | -$3,434,672 | +$94,228,548 | NTRA, TMO, GH, CDNA, TECH | 13F-HR | 14 Feb 2022, 14:49 |
| Q3 2021 | 23 | $306,758,000 | +$139,032,818 | -$88,940,181 | +$50,092,637 | NTRA, CDNA, TMO, TECH, A | 13F-HR | 15 Nov 2021, 16:18 |
| Q2 2021 | 21 | $265,139,000 | +$94,353,777 | -$43,031,989 | +$51,321,788 | NTRA, CDNA, AMRSQ, TMO, NEO | 13F-HR | 13 Aug 2021, 12:03 |
| Q1 2021 | 23 | $204,307,000 | +$35,185,670 | -$18,829,596 | +$16,356,074 | AMRSQ, CDNA, NTRA, GH, EXAS | 13F-HR | 14 May 2021, 13:56 |
| Q4 2020 | 21 | $170,376,000 | $0 | CDNA, NTRA, GH, CELL, AMRSQ | New Holdings | 14 May 2021, 13:59 | ||
| Q4 2020 | 11 | $165,150,000 | $0 | CDNA, NTRA, GH, CELL, AMRSQ | 13F-HR | 16 Feb 2021, 05:11 |